NIKKEI 225
38,783.27 -116.75 (-0.30%) HANG SENG
18,873.41 +46.06 (+0.24%) CRUDE OIL
78.90 +1.18 (+1.52%) GOLD FUTURES
2,354.50 +20.00 (+0.86%) DOW
39,069.59 +4.29 (+0.01%) Bitcoin GBP
53,582.59 -438.61 (-0.81%)
AVIR Oct 2024 2.500 put
| Previous close | 0.1000 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.1500 |
| Strike | 2.50 |
| Expiry date | 2024-10-18 |
| Day's range | 0.0500 - 0.0600 |
| Contract range | N/A |
| Volume | |
| Open interest | 6.14k |
GlobeNewswireAtea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases,
- GuruFocus.com
Atea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...
Discover key updates on Atea's financial health, clinical advancements, and strategic outlook as they pave the way through 2024.
- GlobeNewswire
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to be Presented at European Association for the Study of the Liver (EASL) Congress 2024 Conference Call at 4:30 pm ET Today BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-s
